AbbVie reported a Phase 3 win for its T-cell engager etentamig in multiple myeloma, meeting the trial’s main goal. Company results indicated a 60% risk reduction for disease progression or death compared with standard regimens, with safety data emphasizing low rates of serious immune-related adverse events relative to comparator therapies. The program enrolled 421 patients and moved through an interim checkpoint that triggered unblinding after independent trial monitors detected differences. AbbVie framed the profile as potentially enabling broader use in community oncology by reducing post-treatment monitoring intensity.